Capitolul 9 - BIBLIOGRAFIE - Ghid din 2019 privind terapia menopauzei
M.Of. 738 bis
În vigoare Versiune de la: 10 Septembrie 2019
CAPITOLUL 9:BIBLIOGRAFIE
SECŢIUNEA 1:INTRODUCERE
1.Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Citkova R, de Muinck Keizer-Schrama S, Hegervorst E, Jansen E, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N-European Society for Human R, Embryology Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016; 31:926-937
2.Manson JA, Aragaki AK, Rossouw EJ, Anderson GL, Prentice LR, laCroix ZA, Chlebowski TR, Howard VB, Thomson AC, Margolis L K, Lewis EC, Stefanick LM, Jackson DR, Johnson CK, Martin WL, Shumaker AS, Espeland AM, Wactawski-Wende J, for the WHI - Menopausal hormone therapy and long term all- cause and cause-specific mortality. JAMA. 2017, 318, 927-938doi:10.1001/jama.2017.11217
3.McKinlay MS, Brambilla DJ, Posner JD (1992) - The normal menopause transition. Maturitas 14, 105-15
4.North American Menopause Society (2005) - USA management in menopause. www.menopause.org.
5.World Health Organization Scientific Group. Research on the Menopause in the 1990s. Geneva, Switzerland: World Health Organization; 1996. WHO Technical Report Series 866.
6.Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Climacteric. 2001; 4(4):267-272.
7.Avis NE, Crawford SL, Greendale G, Bromberger JT, Evereson Rose AS, Gold BE, Hess R, Joffe H, Kravitz, Tepper GP, Thurston CR, for the Study of Women's Health Across the Nation (SWAN) - Duration of menopausal vasomotorsymptoms over the menopause transition. JAMA Internal Medicine. 2015; 175, . 531-539.
8.Roberts H, Hickey M - Managing the menopause; An update. Maturitas 2016 Apr; 86:53-8.doi:10.1016
9.Freeman EW, Sammel MD, LinH, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol. 2011; 117(5):1095-1104.
10.Freeman E, Sammel MD, Sanders RJ. - Risk of long termhot flashes after natural menopause:evidence from the Penn Ovarian Aging Cohort Menopause. 2014; 21, 924-932
11.Slopien R, Wichniak A, Pawlak M, Slopien A, Szymankiewiics A, Sajdak S. Disturbances of sleep continuity in women during the menopausal transition. Pshychiatr Pol. 2015; 49(3):615-23/
12.Baker FC, Lampio L, Saaresranta P, Polo- Kantola P- Sleep and Sleep Disorders in the Menopausal Transition. Sleep Med Clin2018; 13(3):443-456.
13.Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, DubeR, Cote I, Labriee C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2009) - Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy..Maturitas., 16(5):907-22
14.Traish MA, Vignozzi L, Simon AJ, Goldstein I, Kim NN (2018) - Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sexual Medicine Reviews. 6(4), 558-571
15.American Cancer Society (2002) - Special Section: Colorectal Cancer and Early Detection. Cancer Facts & Figures
16.Bromberger JT, Schott LL, Kravitz HM, Sowers M, Avis NE, Gold EB, Randolph JF Jr, Matthews KA Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN).Arch Gen Psychiatry 2010; 67(6):598-607.doi:10.1001/archgenpsychiatry.2010.55.
17.Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res. 1999; 105(1):53-68.
18.Slopień R, Pluchino N, Warenik- Szymankiewics A, Sajdak S, Luisi M, Drakopoulos P, Genazzani AR - Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause.Gynecol Endocrinol 2018 Feb; 34(2):144-147.
19.Acs N, Vajo Z, Miklos Zsuzsanna, Paulin F, et al (2000) - Postmenopausal Hormone Replacement Therapy and Cardiovascular Mortality in Central-Eastern Europe The Journals of Gerontology Series A. Biological Sciences and Medical Sciences; 55: M160-M162.
20.Grodstein F, Stampfer MJ, Colditz GA (1997) - Postmenopausal hormone therapy and mortality. N Engl J Med: 336: 1769-1775.
21.Stevenson JC, Flather M, Collins P (2000) - Coronary heart disease in women. N Engl J Med; 343:1891-3.
22.Thurston CR, Sutton- Tyrrell K, Everson-Rose SA, Hess R, Matthews KA (2008) - Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008; 118 (12):1234-40.
23.Wildman RP, Colvin AB, Powell LH, Matthews KA, Everson-Rose SA, Hollenberg S, Johnston JM, Sutton-Tyrrell K (2008). Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN) Menopause. 2008; 15:414-421
24.Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) - Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39:257-265.
25.Thurston CR, Chang Y, Barinas-Mitchell, Jennings JR, Landssittel DP, Santoro N, von Kanel R, Matthews KA. Menopausal hot flashes and carotid intima media thickness among midlife women. STOKE 2016; 47(12):2910-2915.
26.Thurston CR, Sutton-Tyrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima media thickness among midlife women. MENOPAUSE. 2011 Apr; 18(4): 352-8.
27.Ho JE, Mosca L (2002) - Postmenopausal hormone replacement therapy and atherosclerosis. Curr Atheroscler Rep: 2002, 4 (5): 387-95.
28.McCarrey AC, An Y, Kitner-Triolo MH, Ferrucci L, Resnick SM- (2016) - Sex differences in cognitive trajectories in clinically normal older adults. Psychol Aging. 2016; 31(2):166-175
29.Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16:15-23.
30.Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al (2012) - . Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th european stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012; 34:290-296.
31.Lambrinoudaki I, Augoulea A, Armeni E, Rizos D, Alexandrou A, Creatsa M, et al.(2012) - Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric.; 15:350-357.
32.Hodis HN, Mack WJ. (2011) - A window of opportunity: the reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res.; 1379:244-252.
33.Salpeter SR, Walsh JME, Greyber E, et al.(2006) - Coronary heart disease events associated with hormone therapy in younger and older women: A meta-analysis. J Gen Intern Med.; 21: 363-366.
34.Salpeter SR, Walsh JME, Greyber E, et al (2004) - Mortality associated with hormone replacement therapy in younger and older women: A meta-analysis. J Gen Intern Med.; 19:791-804.
35.Bainbridge KE, Sowers MF, Crutchfield M, Lin X, Jannausch M, Harlow SD.(2002) - Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am. J. Epidemiol.; 156(5), 410-417.
36.Vondracek SF, Hansen LB, McDermott MT- Osteoporosis risk in premenopausal women. Pharmacotherapy 2009; 29(3), 305-317.
37.National Osteoporosis Foundation. What Women Need to Know.National Osteoporosis Foundation, Washington, DC, USA, 2013.
38.CanoA, et al (2017) - Calcium in the Prevention of Postmenopausal Osteoporosis: EMAS Clinical Guide" Maturitas. 2017.doi.org/10.1016/j. 7.10.004.
39.Martinez-Morillo M, Grados D, Holgado S (2012) - Premenopausal osteoporosis: how to treat? Rheumatol. Clin.; 8(2), 93-97.
40.NIH Osteoporosis and Related Bone Diseases National Resource Center. Osteoporosis: Peak Bone Mass in Women. 2012; NIH, Bethesda, MD, USA.
41.Cohen A, Fleischer J, Freeby M, McMahon D, Irani D, Shane E (2009) - . Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J. Womens Health 2009; 18(1), 79-84.
42.McLendon NA, BrockWoodis C-(2014) - A review of osteoporosis management in young premenopausal women.s health. Women's Health, 2014; 13 (3); 59-77.
43.Peris P, Monegal A, Martinez MA, Moll C, Pons F, Guanabens N (2007) - Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin. Rheumatol. 2007; 26(6), 958-961.
44.Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y (1990) - Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J. Haematol:74: 77-81.
45.Winkler UH (1992) - Menopause, hormone replacement therapyand cardiovascular disease: a review of haemostareological findings.Fibrinolysis:6 (suppl 3): 5-10.
46.Godsland FI, Crook D, Stevenson JC, Collins P, Rosano GMC, Lees B, Sidhu M, Poole Wilson PA (1995) - The insulin resistence syndrome in postmenopausal women with cardiological syndrome X. Br.Heart J.:74: 47-52.
47.Godsland FI, Stevenson JC (1995) - Insulin resistence: syndrome or tendency. Lancet: 346: 100-103.
48.Anagnostis P, Christou K, Artzouchaltzi A-M, Paschou SA, Potoupnis M, Tsiridis E, Lambrinoudaki I, Goulis DG (2018) - Early menopause and premature ovarian failure are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. 54th EASD Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, 01-05/10/18; Diabetologia 2018, 61 (Suppl 1):S445.
49.Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al(1992) - Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med: 117: 1016-37.
50.North American Menopause Society (2005) - USA management in menopause. www.menopause.org.
51.American Cancer Society (2002) - Special Section: Colorectal Cancer and Early Detection. Cancer Facts & Figures.
52.Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. (2011) - Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry 2011; 72:e1563-e1569.
53.Yonkers KA, O'Brien PM, Eriksson E (2008) - Premenstrual syndrome. Lancet; 371:1200-1210.
54.Bloch M, Rotenberg N, Koren D, Klein E - (2006) -Risk factors for early postpartum depressive symptoms. Gen Hosp Psychiatry; 28:3-8.
55.Arpels JC (1996) - The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med 1996; 41:633-639.
SECŢIUNEA 2:METODOLOGIE DE ELABORARE ŞI REVIZIE
1.Asociaţia Medicală de Menopauză din România (AMMR) (2004) - Consensul privind terapia hormonală pentru menopauză al Asociaţiei Medicale de Menopauză din România. Sinaia, 27-29 februarie 2004
2.Lewiecki EM, Watts NB, McClung MR, et al. (2004) - Official positions of the international society for clinical densitometry. J. Clin. Endocrinol. Metab. 2004; 89(8), 3651-3655 (The diagnostic criteria for premenopausal osteoporosis are contained in these guidelines. The need for additional fracture risks beyond low Z-scores is also discussed)
3.Canonico M, Oger E, Plu-Bureau G, et al.(2007) - Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-845.
4.National Osteoporosis Foundation. What Women Need to Know. National Osteoporosis Foundation, Washington, DC, USA (2013).
5.Hodis HN, Shoupe D, Azen SP, Henderson VW, et al. (2014) - Testing the menopausal hormone therapy timing hypothesis: the Early versus Late Intervention Trial with Estradiol (ELITE). Circulation. 2014; 22(4):391-401.
6.Stuenkel CA, Davis SR, Gompel A, et al-(2015) Treatment of symptoms of the Menopause. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100; 3975 http://www.cancer.gov/bcrisktool/.
7.Barber RJ, Panay N, Fenton A, and the IMS Writing Group (2016) - . IMS Recommendations on womem's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109-150
8.Bassuk SS, Manson JE. The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism, 2016; 65(5):794-803.
9.De Villiers TJ, Hall JE, Pinkerton JV, Cerdas Perez S, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016 Aug. 19(4):313-5.
10.The Nams 2017 - Hormone therapy position statement advisory panel. The 2017 hormone therapy position statement of the north amenrican menopause society. Menopause 2017; 24:728.
11.Haelle T. (2016) - New Menopause Guidelines Update HT Safety Evidence. Medscape Medical News. August 18, 2016. Available at http://www.medscape.com/viewarticle/867600.
12.Barber RJ, Panay N, Fenton A, and the IMS Writing Group (2016) - IMS Recommendations on womem's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109-150
13.Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (Gynecology and Fertility Group) (2017) - Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, 2017, CD004143.
14.Mikkila TS, Savolainen-Peltonen H et al. New evidence for cardiac benefic of postmenopausal hormone therapy. Climacteric; 20(1):5-10.
15.US preventive services task force. Grossman DC, Curry SJ et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: Recommendation statement. Jama 2017 Dec 12.318(22):2224-2233.
SECŢIUNEA 3:EVALUARE ŞI DIAGNOSTIC
1.Cohen A, Fleischer J, Freeby M, McMahon D, Irani D, Shane E. (2009) - Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J. Womens Health; 18(1), 79-84.
2.Compston Juliet(2005) - Guidelines for the management of osteoporosis: the present and the future Osteoporosis International Journal vol 16, no 10
3.Vondracek SF, Hansen LB, McDermott MT (2009) - Osteoporosis risk in premenopausal women. Pharmacotherapy; 29(3), 305-317.
SECŢIUNEA 4:CONDUITĂ
1.National Institute for Health and Care Excellence (NICE) (2015) - UK guideline 23 on Menopause: Diagnosis and Management, published in November 2015.
2.Hodis HN, Shoupe D, Azen SP, Henderson VW, et al.(2014) - Testing the menopausal hormone therapy timing hypothesis: the Early versus Late Intervention Trial with Estradiol. Circulation. 2014; 22(4):391-401.
3.Hodis HN, Mack WJ et al. Vascular effects of early vs late postmenopausal treatment with estradiol. NEJMED; 374(13)1221-31.
4.Mikkola TS, Savolainen-Peltonen H, Venetkoski M et al. New evidence for cardiac benefit of postmenopausal hormone therapy. Climacteric; 20(1):5-10.
5.Kung AW, Chan TM, Lau CS, Wong RW, Yeung SS (1999) - Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology; 38(12), 1239-1244.
6.Gleason CE, Dowling NM, Wharton W, et al.(2015) - Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med; doi: 12:e1001833.
7.Joffe H, Soares CN, Petrillo LF, et al. (2007) - Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry; 68:943.
8.Worsley R, Davis SR, Gavrilidis E, et al. (2012) - Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas; 73:127.
9.Barnabei VM, Cochrane BB, Aragaki AK, et al.(2005) - Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol; 105:1063.
10.Chlebowski RT, Cirillo DJ, Eaton CB, et al (2013) - Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause; 20:600.
11.The NAMS 2017-Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause; 24:728.
12.Scarabin PY, Oger E, Plu-Bureau G.(2003) - Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet; 362: 428-432.
13.Canonico M, Oger E, Plu-Bureau G, et al.(2007) - Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-845.
14.Million Women Study Collaborators (2003) - Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet; 362: 419-427.
15.Sunday Lorraine, Tran MM, Krause N. Diana, Duckles P. Sue(2006) - Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab, 291: 261-7.
16.Simon JA, Hsia J, Cauley JA, et al. (2001) - Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation; 103:638-642.
17.Cicinelli E, Ziegler D, Bulletti C, Matteo Maria Giuseppina, Schonauer LM, Galantino P (2000) - Direct Transport of Progesterone From Vagina to Uterus: Obstetrics & Gynecology; 95: 403-406.
18.The Writing Group for the PEPI Trial (1995) - Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 273:199- 208.
19.Fitzpatrick LA, Good A (1999) - Micronized progesterone: Clinical indications and comparison with current treatments. Fertility Sterility, : 72(3): 389-397.
20.Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torlonii MR- Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev, 2018, (8):CD010407. doi: 10.1002/14651858.CD010407.pub2.
21.Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, CoteI, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt LM, Balser J, Moyneur E, VVA Prasterone Research Group(2016) - . Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause.; 23(3):243-256.
22.Traish MA, Vignozzi L, Simon AJ, Goldstein I, Kim NN (2018) - Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sexual Medicine Reviews. 6(4), 558-571.
23.The Women's Health Initiative Steering Committee (2004) - Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA; 291:1701-1712.
24.Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (Gynecology and Fertility Group) (2017) - Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, 2017, CD004143.
25.Societe d'Obstetrique et Gynecologiede Canada (SOGC) (1998) - Hormone Replacement Therapy: an update... the benefits of HRT and counseling issues related to breast cancer. SOGCClinical Practice Guidelines. Policy statement no.73.
26.Roussouw JE, Prentice RL et al (2002) - Risks and benefits of estrogen plus progestins in healthy postmenopausal women: principal results from the WHI randomized controlled trial. JAMA: 288: 321- 333
27.Martin KA, Manson JE (2008). Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008; 93:4567.
28.Manson JA, Aragaki AK, Rossouw EJ, Anderson GL, Prentice LR, laCroix ZA, Chlebowski TR, Howard VB, Thomson AC, Margolis L K, Lewis EC, Stefanick LM, Jackson DR, Johnson CK, Martin WL, Shumaker AS, Espeland AM, Wactawski-Wende J, for the WHI(2017) - Menopausal hormone therapy and long term all - cause and cause-specific mortality.JAMA., 318, 927-938.
29.Van de Weijer PHM, Barentsen P (1998) - Estrogen replacement and vaginal bleeding. Menopause Review, ; vol 3: 13-6.
30.Thomas AM, Hickey M, Fraser IS (2000) - Disturbances of endometrial bleeding with hormone replacement therapy.Hum. Reprod., 15, suppl 3: 7-17.
31.Sturdee DW, Barlow D H, Ulrich LG (1994) - Is the timing of withdrawl bleeding a guide to endometrial safety during sequential oestrogen- progestogen replacement therapy?, Lancet, 344: 979-82.
32.Whitehead M I, Hillard T C, Crook D (1990) - The role and use of progestogens, Obstet.Gynecol, 75:59-76.
33.Karlsson B, Granberg S, Wikland M, Ylöstalo P, Torvid K, Marsal K, Valentin L (1995) -Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am.J. of Obstetr.&Gyn, 172, 1488-94.
34.Granberg S, Wickland M, Karlsson B (1991) - Endometrial thickness as measured by endovaginal ultrasound for indentifying endometrial abnormality.Am. J. Obst.Gyn., 164; 47-52.
35.Studd JW, Zakaria FBP (1997) - The management of hormone replacement therapy, bleeding and compliace, Gynaecol. Endocrinol., Vol 11, Suppl.2, 5-10.
36.Archer DF, Pickar JH, Bottiglioni F (1994) - Bleeding patterns in postmenopausal women taking continuos combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate, for the Menopause Study Group, Obstetrics & Gynecol, 83, 686-693
37.Stuenkel CA, Davis SR, Gompel A, et al- (2015) Treatment of symptoms of the Menopause. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab.; 100; 3975.
38.http://www.cancer.gov/bcrisktool/.
39.MacLennan AH, Broadbent JL, Lester S, Moore V. (2004) - Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev.
40.The North American Menopause Society (2004) - Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause; 11(1):11-33.
41.Sanchez KC, Rumbellow S (2018) - Hormone Replacement Therapy for Menopausal Symptoms. US Pharm. 2018; 43(9):21-26.
42.Palacios S, Silverman SL, de Villiers TJ, et al.(2015) - A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause; 22(8):806-813.
43.ACOG Practice Bulletin No. 141 (2014) - Management of menopausal symptoms. Obstet Gynecol. 2014; 123(1):202-216.
44.Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. (2005) Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol; 105:161-166.
45.Stearns V, et al. (2003) - Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA, 289(21): 2827-2834.
46.von Schoultz E, Rutqvist LE (2005) -Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.J Natl Cancer Inst; 97: 533-535
47.Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. (2006) - Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J; 12:114-122.
48.Borrelli F, Ernst E (2002) - Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol:58: 235-241.
49.Krebs EE, Ensrud KE, et al. (2004) - Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic Review. Obstet Gynecol104: 824-836.
50.Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L (1998) - Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol; 92:722-727.
51.Palacios S, Castelo-Branco C, Currie H, et al. (2015) - Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 2015; 82:307-12.
52.Shaywitz SE, Shaywitz BA, Pugh KR, et al (1999) - Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA; 281:1197-202.
53.Rasgon NL, Magnusson C, Johansen A L, et al. (2005) -Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: a preliminary study. Psychoneuroendocrinology; 30: 558-67.
54.Herrigton DM, Fong J, Sempos CT (1998) - Comparison of the Estrogen/Progestin replacement Study (HERS) cohort with coronary disease from the National Health and Nutrition Examination Survey (NHANES III). Amer. Heart J:136: 115-124.
55.Barber B, Daley S, O'Brien J. (2005) Dementia.In Menopause, postmenopause and ageing. Eds Keith L, Rees M, Mander T. p20-34.
56.Zandi PP, Carlson MC, Plassman BL, et al.(2002) - Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA.; 288(17):2123-9.
57.Henderson VW. Cognition and cognitive aging. Climacteric. Suppl 2:88-91.
58.Maki PM (2012) - Minireview: effects of different HT formulations on cognition. Endocrinology; 153, 3564-3570
59.Maki PM (2015) - Verbal memory and menopause. Maturitas. 2015; 82(3):288-290.
60.Shumaker SA, Legault C et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 289(20):2651-62.
61.Espeland MA, Rapp SR, Shumaker SA, et al (2004) - Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA; 291: 2959-68.
62.Tolppanen AM, Tiihonen M, Taipale H, Koponen M, Tanskanen A, Lavikainen P, Tiihonen J, Hartikanen S (2018) - Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005-2012: A Nationwide Exposure-Matched Cohort Study. Drugs Aging. 2018; 35 (11):985-997.
63.Swegle JM, Kelly MW. (2004) - Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother; 38: 874-81.
64.Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Moellgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004). Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone; 34: 728-35.
65.Ettinger B, Black DM, Mitlak BH, et al.(1999) - Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA; 282:637-645
66.Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. (2004) -Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res; 19:1270-1275.
67.Delmas PD, Bjarnason NH, Mitlak BH, et al.(1997) - Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med; 337:1641-1647.
68.Barrett-Connor E, Mosca L, Collins P, et al. (2006) - Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med; 355:125-137.
69.Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD; MORE Investigators (2002) - Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA; 287: 847-857.
70.Vogel VG, Costantino JP, Wickerham DL, et al. (2006) - Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA; 295: E1-15.
71.Barclay Laurie (2006) - Updated Position Statement for Calcium Intake in Postmenopausal Women. Menopause; 13: 859-862.
72.Grodstein F, Stampfer MJ, Colditz GA, et al for Nurses' Health Study (1997) - Postmenopausal hormone therapy and mortality. N Engl J Med: 336 (25): 1769-75.
73.Herrigton DM, Fong J, Sempos CT (1998) - Comparison of the Estrogen/Progestin replacement Study (HERS) cohort with coronary disease from the National Health and Nutrition Examination Survey (NHANES III). Amer. Heart J:136: 115-124.
74.Hulley S, Grady D, Bush T, furberg C, Herrington D, Riggs B; Vittinghoff E for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. (1998)Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.JAMA, Vol. 280 No. 7, 605-613.
75.Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group (2002) - Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA; 288:58-66.
76.Clarke SC, Kelleher J, Lloyd-Jones H, et al (2002) - A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJO; 109:1056-1062.
77.Hodis HN, Mack WJ, Lobo RA, et al (2001) - Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2001; 135: 939-953.
78.Hodis HN, Mack WJ, Azen SP, Lobo RA, et alforWomen's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group (2003) - Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med.; 349 (6): 535-45.
79.Grodstein F, Manson JE, Stampfer MJ (2006) - Hormone therapy and coronary heart disease: the role of time since menopauseand age at hormone initiation. J Women's Health; 15:35-44.
80.Adams MR, Kaplan JR, Manuck SB, Koritinik DR, Parks JS, Wolfe MS, Clarkson TB (1990) - Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 10: 1051-1057.
81.Adams RM, Register C T, Golden L Deborah, Wagner D Janice, Williams J. K (1997) - Medroxyprogesterone Acetate Antagonizes Inhibitory Effects of Conjugated Equine Estrogens on Coronary Artery Atherosclerosis. Arteriosclerosis, Thrombosis, and VascularBiology. 17: 217-221.
82.Phillips LS, Langer DR-Emory and UCSD Researchers Offer New Unifying Hypothesis to Guide Postmenopausal Hormone Therapy.Fertility and Sterility, May, 2005.
83.Gervat M-O, Stevenson CJ (2017) - Establishing the risk related to hormone replacement therapy and cardiovascular disease in women. Clinical Pharmacist, 9 (1) online. DOI: 10.1211/CP.2017.20202066.
84.Stevenson J (2005) - Hormone replacement therapy and cardiovascular disease. The Obstetrician & Gynecologist, 7 (1), 1-4.
85.de Vries CS, Bromley S.E, Farmer RDT (2006) - Myocardial infarction risk and hormone replacement therapy. Differences between produces. Maturitas, 53, 3, 343-351.
86.Cushman M, Legault C, Barrett-Connor E, et al.(1999) - Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999; 100: 717-722.
87.Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM (2005) - Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost.; 93(6):1108-16.
88.Oger E, Alhenc-Gelas M, Plu-Bureau G, Mennen L, Cambillau M, Guize L, Pujol Y, Scarabin PY (2001) - Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. Thromb Res; 101 (2): 35-43.
89.Lacut K, Oger E, Abalain JH, et al; SARAH Investigators (2004) - Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial. Atherosclerosis; 174 (1):173-80.
90.Modena MG, Sismondi P, Mueck AO, Kutten F, Lignieres B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TheTREAT(2005) - New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.Maturitas 52-55.
91.Oger E, Alhenc-Gelas M, Lacut K, Scarabin PY, Mottier D, et al SARAH Investigators (2003) - Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Atheroscl. ThrombVasc Biol; 23(9):1671-6.
92.Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL (2004). Evidence-based guidelines for cardiovascular disease prevention in women. Circulation; 109: 672-693.
93.Hoibraaten E, Abdelnoor M, Sandset PM (1999) - Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost: 82 (4): 1218-21.
94.Sesso HD, Paffenbarger RS, Ha T, et al. (1999) - Physical activity and cardiovascular disease risk in middle-aged and older women. Am J Epidemiol; 150: 408-16.
95.Shepherd J, Blauw GJ, Murphy MB, et al. (2002) - Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet; 360: 1623-30.
96.Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) - A clinical trial of estrogen replacement therapy after ischemic stroke. New Engl. J. Med: 345: 1243-49.
97.Curb J. D, Prentice LR, Bray P, Langer DR, Van Horn Linda, Barnabei M.Vanessa, et al (2006) - Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Intern Med; 166: 772-780.
98.Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson FB, Rosendaal FR, Psaty BM (2004) - Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis JAMA; 292 (13): 1581-7.
99.Straczek C, Oger E, Yon de Jonage- Canonico MB, Plu- Bureau G, Scarabin PY et al, Estrogen and THromboEmbolism Risk (ESTHER) Study Group (2005) - Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation; 112 (22): 3495-500.
100.Oger E, Alhenc- Gelas M, Lacut K, Scarabin PY, Mottier D, et al SARAH Investigators (2003) - Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Atheroscl. ThrombVasc Biol; 23(9):1671-6.
101.Douketis J (2005) - Hormone replacement therapy and risk for venous thromboembolism: what's new and how do these findings influence clinical practice? Curr Opin Hematol; 12 (5): 395- 400.
102.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petiti D (1995) - HRTand endometrial cancer risk, a meta- analysis.Obst.- Gynecol., 1995, 85, 304-313.
103.Adami H-O, Persson I, Hoover R, Schairer Catharine, Bergkvist L (1989) - Risk of cancer in women receiving hormone replacement therapy. Int.J. Cancer; 44: 833-839.
104.Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I (1999) - Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Int: 91 (13): 1131-7.
105.Hill A. Deirdre, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, Self S, National Cancer Institute (2000) - Continuous Combined HRT May Decrease Endometrial Cancer Risk.American Journal Obstetrics and Gynecology; 183: 1456-1461.
106.Wells M, Sturdee W D, Barlow HD, Ulrich G Lian, O'Brien Karen, Campbell J M, Vessey P M, Bragg JA for the UK Continuous Combined Hormone Replacement Therapy Study Investigators(2002) - Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study BMJ; 325: 239.
107.Ettinger B, Li DK, Klein R (1998) - Unexpected vaginal bleeding and associated gynaecologic care in postmenopausal women using hormone replacement therapy; comparison of cyclic versus continuos combined schedules. Fertil- Steril, 69(5), 865-9.
108.Ylikorkala O, Wahlstrom T, Caubel P, Lane R (2002) -Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate. Acta Obstet Gynecol Scand.; 81 (7):654-60.
109.Rodriguez Carmen, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW Jr (1995) Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1; 141 (9): 828-35.
110.Garg PP, Kerlikowske K, Subak L, Grady D (1998) - Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol; 92 (3): 472-9.
111.La Vecchia C, Brinton LA, McTiernan A (2002) - Cancer risk in menopausal women. Best Pract Res Clin Obstet Gynaecol; 16:293-307.
112.Anderson GL, Judd HL, Kaunitz AM, et al; Women's Health Initiative Investigators. (2003) - Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA290: 1739-48.
113.Collaborative Group on Hormone Factors in Breast Cancer (1997) - Breast cancer and HRT. Lancet: 350; 1047-59.
114.Chlebowski RT, Anderson GL, Gass M, et al. (2010) - Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20. 304(15):1684-92.
115.Chlebowski RT, Hendrix SL, Langer RD, et al. (2003) - Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA; 289:3243-3253.
116.Stevenson J (2005) - Hormone replacement therapy and cardiovascular disease. The Obstetrician & Gynecologist, 7 (1), 1-4.
117.Stefanick ML, Anderson GL, Margolis KL, et al. (2006) - Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA; 295:1647-57.
118.Fernandez E, Franceschi Silvia, La Vecchia C (2000) Colorectal cancer and hormone replacement therapy. A review of epidemiologic studies. J Br Meno Soc: 6:1:8-14.
119.Grodstein F, Newcomb PA, et al. (1999) - Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med. 106: 574-582.